Novo Nordisk A/S $NVO Stock Holdings Boosted by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its holdings in Novo Nordisk A/S by 15.6%, acquiring an additional 35,329 shares for a total worth of $18.14 million.
• The stock price of Novo Nordisk A/S rose to $56.89 after a trading volume of nearly 17.87 million shares, yet the company's one year high remains at $139.74.
• Novo Nordisk announced a semi-annual dividend of $0.4119 per share, with a total payout ratio currently at 22.53%.

Charles Schwab Investment Management Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 15.6% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 261,243 shares of the company's stock after buying an additional 35,329 shares during the period. Charles Schwab Investment Management Inc.'s holdings in Novo Nordisk A/S were worth $18,141,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. North Star Investment Management Corp. boosted its stake in shares of Novo Nordisk A/S by 18.2% in the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock valued at $1,440,000 after purchasing an additional 3,200 shares during the period. Bank of New York Mellon Corp lifted its holdings in Novo Nordisk A/S by 6.0% in the 1st quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company's stock worth $58,316,000 after buying an additional 47,804 shares in the last quarter. Stanley Laman Group Ltd. purchased a new position in Novo Nordisk A/S in the 1st quarter valued at about $390,000. Dover Advisors LLC purchased a new position in Novo Nordisk A/S in the 1st quarter valued at about $505,000. Finally, GAMMA Investing LLC grew its stake in shares of Novo Nordisk A/S by 9.6% during the first quarter. GAMMA Investing LLC now owns 9,466 shares of the company's stock valued at $657,000 after acquiring an additional 827 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded up $1.4410 during trading hours on Friday, reaching $56.8910. The company's stock had a trading volume of 17,869,499 shares, compared to its average volume of 29,123,660. The company's 50 day simple moving average is $62.57 and its 200 day simple moving average is $69.45. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $139.74. The stock has a market cap of $254.02 billion, a P/E ratio of 15.63, a price-to-earnings-growth ratio of 1.93 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date is Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's payout ratio is currently 22.53%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target for the company in a report on Wednesday, August 13th. Hsbc Global Res lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BNP Paribas raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. Finally, Wall Street Zen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Three analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.